Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

STRO-004

Antibody-drug conjugate · Cytotoxic, directed at tissue factor (F3) · developed by Sutro Biopharma

Phase 1 Most advanced trial
STRO Developer
1 Registered trials

What is STRO-004?

STRO-004 is an antibody-drug conjugate in which an Fc-silent IgG1 antibody against tissue factor (F3) is linked to the topoisomerase I inhibitor exatecan. After binding TF on tumor cells and internalization, exatecan is released, causing DNA damage and apoptosis, and it also kills neighboring TF-negative cells. It is studied in head and neck, lung, esophageal, gastric, colorectal, pancreatic, cervical, endometrial and urothelial cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
tissue factor (F3)
Mechanism
Cytotoxic, directed at tissue factor (F3)
Pathways
DNA topoisomerase I inhibition, DNA damage and apoptosis, bystander killing of TF-negative tumor cells, angiogenesis
Therapy area
Oncology
Developer
Sutro Biopharma, Inc. (STRO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07227168 Phase 1 Head and Neck Squamous Cell Carcinoma HNSCC Recruiting STRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical CancerColorectal CancerEndometrial CancerEsophageal CancerGastric CancerHead and Neck Squamous Cell Carcinoma HNSCCNon-Small Cell Lung Cancer NSCLCPancreatic Ductal Adenocarcinoma (PDAC)Urothelial Cancer

More from Sutro Biopharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the STRO page.

Follow STRO, the company behind STRO-004

See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STRO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.